BioVaxys Technology (XCNQ:BIOV) YoY EBITDA Growth : -66.67% (As of Jan. 2025)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. BioVaxys Technology's YoY EBITDA Growth for the quarter that ended in Jan. 2025 was -66.67%.

BioVaxys Technology's EBITDA per Share for the three months ended in Jan. 2025 was C$-0.01.

BioVaxys Technology YoY EBITDA Growth Historical Data

The historical data trend for BioVaxys Technology's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology YoY EBITDA Growth Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

YoY EBITDA Growth

Get a 7-Day Free Trial

-85.71

-100.00

46.15

-14.29

64.58

BioVaxys Technology Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
YoY EBITDA Growth	Get a 7-Day Free Trial															62.50	50.00	84.62	-	-66.67

BioVaxys Technology YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

BioVaxys Technology's YoY EBITDA Growth for the fiscal year that ended in Oct. 2024 is calculated as:

	YoY EBITDA Growth (A: Oct. 2024 )
=	(EBITDA per Share (A: Oct. 2024 )	-	EBITDA per Share (A: Oct. 2023 ))	/	\| EBITDA per Share (A: Oct. 2023 ) \|
=	(-0.017	-	-0.048)	/	\| -0.048 \|
=	64.58 %

BioVaxys Technology's YoY EBITDA Growth for the quarter that ended in Jan. 2025 is calculated as:

	YoY EBITDA Growth (Q: Jan. 2025 )
=	(EBITDA per Share (Q: Jan. 2025 )	-	EBITDA per Share (Q: Jan. 2024 ))	/	\| EBITDA per Share (Q: Jan. 2024 )) \|
=	(-0.005	-	-0.003)	/	\| -0.003 \|
=	-66.67 %

BioVaxys Technology YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (XCNQ:BIOV) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

BVAXF:USA 5LB:Germany

Address

595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

Executives

James Passin	Director, Senior Officer
Kenneth Kovan	Senior Officer

BioVaxys Technology Headlines

No Headlines